Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Trial Details

NCT ID
NCT06376669
Phase
PHASE2
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Proton Stereotactic Body Radiation therapy (SBRT)
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

  • Age ≥ 18 years
  • Biopsy proven renal cell carcinoma.
  • No clinical or radiographic evidence of metastatic disease.
  • Not a candidate for surgical treatment or local ablative procedures.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →